Exchange: NASDAQ·Updated 07:58 PM EDT
KYMR logo

KYMR Kymera Therapeutics Inc

$108.07
$3.29
(3.14%)
Today
Closed $108.07
$5.43
(5.03%)
After Hours
EarningsNov 3
Mkt Cap$8.71B
Vol683,373.00

About KYMR

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
45

Neutral Sentiment

How do you feel about KYMR?

Merlintrader
Kymera's oral STAT6 degrader KT-621: the Phase 2b BROADEN2 trial in atopic dermatitis has topline data expected by year-end 2026, with Phase 3 planned by mid-2027; cash and investments were $1.5 billion at June 30, 2026 (company, August 5, 2026). Latest company news, September 1, 2026: timing reaffirmed. More details in our $KYMR hub on our site. Not investment advice.

Advertisement|Remove ads.